Business Standard

AstraZeneca Covid-19 vaccine's 90% efficacy came in younger trial group

The vaccine being developed with Oxford University was 90 per cent effective when a half-dose was given before a full-dose booster, the partners said on Monday

Coronavirus, vaccine, covid, drugs, clinical trials
Premium

AstraZeneca reiterated that the data will be published in a peer-reviewed journal in due course

John Lauerman & Angelica LaVito | Bloomberg
The dose of AstraZeneca’s Covid vaccine that showed the highest level of effectiveness was tested in a younger population than a bigger dose that showed less efficacy, according to the head of the US Operation Warp Speed program.

The vaccine being developed with Oxford University was 90 per cent effective when a half-dose was given before a full-dose booster, the partners said on Monday. However, that regime was administered to participants in a group whose age was capped at 55, Warp Speed’s Moncef Slaoui said Tuesday in a phone call with reporters.

Researchers have been puzzling about the AstraZeneca report

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Nov 26 2020 | 1:52 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com